Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $10.82, for a total value of $21,640.00. Following the transaction, the president now owns 2,936,467 shares of the company's stock, valued at $31,772,572.94. The trade was a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Songjiang Ma also recently made the following trade(s):
- On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total value of $22,100.00.
Gyre Therapeutics Price Performance
NASDAQ:GYRE traded up $1.06 during mid-day trading on Monday, reaching $12.20. The company's stock had a trading volume of 111,450 shares, compared to its average volume of 75,067. The firm's fifty day moving average price is $12.86 and its two-hundred day moving average price is $12.61. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.39.
Institutional Investors Weigh In On Gyre Therapeutics
A number of hedge funds have recently added to or reduced their stakes in GYRE. FMR LLC bought a new position in shares of Gyre Therapeutics in the third quarter worth about $47,000. Barclays PLC boosted its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company's stock valued at $116,000 after buying an additional 6,855 shares during the last quarter. Rhumbline Advisers bought a new stake in Gyre Therapeutics in the second quarter worth $123,000. Renaissance Technologies LLC bought a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $166,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
